Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

FDA stung by damning fraudulent research report

Agency accused of leaving untested drugs on the market

- PMLiVE

FDA bars generic version of Purdue’s painkiller OxyContin

New abuse-deterrent formulation means original version no longer has positive benefit-to-risk profile

- PMLiVE

FDA approves return of morning sickness drug for pregnant women

Regulator confirms safety of Diclegis – formerly known as Bendectin

- PMLiVE

Alkermes cuts jobs in Ireland as Novartis invests

130 jobs to go at manufacturing facility in Athlone as Novartis creates 100 roles in Dublin

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

Bayer symbol

Bayer’s riociguat fast-tracked by FDA

Could provide oral option in pulmonary arterial hypertension market

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Merz offers $385m to trump Valeant’s bid for Obagi

Could spark bidding war for dermatology specialist

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links